PD-L1 detection in tumors using [^{64}Cu]atezolizumab with PET
Supporting Information

Wojciech G. Lesniak[1†], Samit Chatterjee[1†], Matthew Gabrielson[1], Ala Lisok[1], Bryan Wharram[1], Martin G. Pomper[1,2] and Sridhar Nimmagadda[1,2*]

[1]Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA.

[2]Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

List of contents:



Scheme S1. Radiolabeling of atezolizumab.



Figure S1. Physicochemical characterization of atezolizumab-DOTAGA conjugate. (**A**) UV-Vis spectroscopy recorded on a Nanodrop 2000 was used to obtain the concentration of atezolizumab-DOTAGA; (**B**) Size Exclusion Chromatography (SEC) performed using a Waters XBridge BEH200A SEC 3.5 µm, 7.8x300 mm column and phosphate buffer (0.1M, pH=6.8) at flow rate of 0.5 mL/min shows narrow molecular weight distribution; (**C**) SDS-PAGE analysis indicating high purity and integrity of atezolizumab and atezolizumab-DOTAGA (**D**) Matrix-Assisted Laser Desorption Ionization Time-of-Flight spectroscopy of atezolizumab (blue line) and atezolizumab-DOTAGA (red line) shows increased molecular weight upon conjugation of DOTAGA to atezolizumab. Increased molecular weight corresponds to two molecules of DOTAGA.

Supplementary Figure 2



Figure S2. Integrity of [^{64}Cu]atezolizumab. Representative images of SDS-PAGE analysis and autoradiography of [^{64}Cu]atezolizumab confirming integrity of the antibody after radiolabeling.